Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1998 1
2000 1
2001 1
2003 2
2005 2
2006 4
2007 7
2008 7
2009 7
2010 6
2011 8
2012 11
2013 10
2014 11
2015 9
2016 13
2017 11
2018 10
2019 8
2020 6
2021 10
2022 6
2023 10

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
State-of-the-art evidence in the treatment of systemic sclerosis.
Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. Pope JE, et al. Nat Rev Rheumatol. 2023 Apr;19(4):212-226. doi: 10.1038/s41584-023-00909-5. Epub 2023 Feb 27. Nat Rev Rheumatol. 2023. PMID: 36849541 Free PMC article. Review.
Pulmonary arterial hypertension is frequently treated with initial combination therapy (for example, with phosphodiesterase 5 inhibitors and endothelin receptor antagonists) and, if necessary, the addition of a prostacyclin analogue. Raynaud phenomenon and digital ulcer …
Pulmonary arterial hypertension is frequently treated with initial combination therapy (for example, with phosphodiesterase 5 inhibitors and …
Update of EULAR recommendations for the treatment of systemic sclerosis.
Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, Distler O, Clements P, Cutolo M, Czirjak L, Damjanov N, Del Galdo F, Denton CP, Distler JHW, Foeldvari I, Figelstone K, Frerix M, Furst DE, Guiducci S, Hunzelmann N, Khanna D, Matucci-Cerinic M, Herrick AL, van den Hoogen F, van Laar JM, Riemekasten G, Silver R, Smith V, Sulli A, Tarner I, Tyndall A, Welling J, Wigley F, Valentini G, Walker UA, Zulian F, Müller-Ladner U; EUSTAR Coauthors. Kowal-Bielecka O, et al. Ann Rheum Dis. 2017 Aug;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909. Epub 2016 Nov 9. Ann Rheum Dis. 2017. PMID: 27941129 Free article.
The procedure resulted in 16 recommendations being developed (instead of 14 in 2009) that address treatment of several SSc-related organ complications: Raynaud's phenomenon (RP), digital ulcers (DUs), pulmonary arterial hypertension (PAH), skin and lung disease, scl …
The procedure resulted in 16 recommendations being developed (instead of 14 in 2009) that address treatment of several SSc-related organ com …
Systemic sclerosis in adults. Part II: management and therapeutics.
Jerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Jerjen R, et al. J Am Acad Dermatol. 2022 Nov;87(5):957-978. doi: 10.1016/j.jaad.2021.10.066. Epub 2022 Feb 4. J Am Acad Dermatol. 2022. PMID: 35131401 Review.
Meanwhile vasculopathy-related manifestations (Raynaud's phenomenon, digital ulcers) and calcinosis, require general measures combined with specific pharmacologic (calcium-channel blockers, phosphodiesterase type 5 inhibitors, and prostanoids), nonpharmacologic ( …
Meanwhile vasculopathy-related manifestations (Raynaud's phenomenon, digital ulcers) and calcinosis, require general measures …
Treatment Algorithms for Systemic Sclerosis According to Experts.
Fernández-Codina A, Walker KM, Pope JE; Scleroderma Algorithm Group. Fernández-Codina A, et al. Arthritis Rheumatol. 2018 Nov;70(11):1820-1828. doi: 10.1002/art.40560. Epub 2018 Sep 17. Arthritis Rheumatol. 2018. PMID: 29781586
For severe RP, the first- through fourth-line treatments were CCBs, then adding PDE5 inhibitors or prostanoids, then adding PDE5 inhibitors (if not added as second-line treatment) or prostanoids (if not added as second-line treatment), then switching to another CCB, respectively. …
For severe RP, the first- through fourth-line treatments were CCBs, then adding PDE5 inhibitors or prostanoids, then adding PDE5 inhibitors …
Calcinosis in scleroderma.
Valenzuela A, Song P, Chung L. Valenzuela A, et al. Curr Opin Rheumatol. 2018 Nov;30(6):554-561. doi: 10.1097/BOR.0000000000000539. Curr Opin Rheumatol. 2018. PMID: 30124603 Review.
It represents a major clinical problem in patients with SSc affecting at least one quarter of patients. It is associated with longer disease duration, digital ulcers, acro-osteolysis, positive anticentromere antibody, and positive anti-PM/Scl antibody. ...
It represents a major clinical problem in patients with SSc affecting at least one quarter of patients. It is associated with longer disease …
[Systemic sclerosis].
Schinke S, Riemekasten G. Schinke S, et al. Internist (Berl). 2019 Dec;60(12):1251-1269. doi: 10.1007/s00108-019-00699-7. Internist (Berl). 2019. PMID: 31754753 Review. German.
Capillaroscopy.
Jung P, Trautinger F. Jung P, et al. J Dtsch Dermatol Ges. 2013 Aug;11(8):731-6. doi: 10.1111/ddg.12137. Epub 2013 Jun 5. J Dtsch Dermatol Ges. 2013. PMID: 23738531 Free article. Review. English, German.
PRINCE (prognostic index for nailfold capillaroscopic examination) was developed to identify patients at high risk of developing systemic sclerosis. CSURI (capillaroscopic skin ulcer risk index) should predict the risk of developing digital ulcers in patients …
PRINCE (prognostic index for nailfold capillaroscopic examination) was developed to identify patients at high risk of developing systemic sc …
Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review.
García de la Peña Lefebvre P, Nishishinya MB, Pereda CA, Loza E, Sifuentes Giraldo WA, Román Ivorra JA, Carreira P, Rúa-Figueroa I, Pego-Reigosa JM, Muñoz-Fernández S. García de la Peña Lefebvre P, et al. Rheumatol Int. 2015 Sep;35(9):1447-59. doi: 10.1007/s00296-015-3241-1. Epub 2015 Apr 1. Rheumatol Int. 2015. PMID: 25824427 Review.
Patient populations had to include adults diagnosed with limited cutaneous or diffuse SSc who had associated RP and/or digital ulcers under pharmacological treatment. Efficacy of treatments was evaluated based on: number of RP episodes, RP severity, episode-free tim …
Patient populations had to include adults diagnosed with limited cutaneous or diffuse SSc who had associated RP and/or digital ulc …
Digital Ulcers in Systemic Sclerosis.
Hughes M, Bruni C, Ruaro B, Confalonieri M, Matucci-Cerinic M, Bellando-Randone S. Hughes M, et al. Presse Med. 2021 Apr;50(1):104064. doi: 10.1016/j.lpm.2021.104064. Epub 2021 Feb 3. Presse Med. 2021. PMID: 33548375 Review.
Digital ulcers (DU) are one of the most common complication of Systemic Sclerosis (SSc)-related vasculopathy and represent an important burden for the patients as well as for the society. ...
Digital ulcers (DU) are one of the most common complication of Systemic Sclerosis (SSc)-related vasculopathy and represent an …
Raynaud's phenomenon and digital ulcers: advances in evaluation and management.
Herrick AL. Herrick AL. Curr Opin Rheumatol. 2021 Nov 1;33(6):453-462. doi: 10.1097/BOR.0000000000000826. Curr Opin Rheumatol. 2021. PMID: 34420003 Review.
RECENT FINDINGS: There have been recent advances in the development of patient reported outcome instruments [e.g. the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU) instrument] and also in noninvasive imaging techniques, including thermography and l …
RECENT FINDINGS: There have been recent advances in the development of patient reported outcome instruments [e.g. the Hand Disability in Sys …
139 results